How is Ilumya administered?

Ilumya is given as a 100 milligram (mg) subcutaneous (under the skin) injection. The first two injections are given 4 weeks apart, followed by an injection once every 12 weeks. Each single-dose prefilled syringe of Ilumya contains 100 mg of tildrakizumab-asmn.

In March, 2018 the FDA approved Ilumya (tildrakizumab-asmn), a humanized interleukin-23 p19 subunit antagonist (anti-IL-23p19) monoclonal antibody for moderate-to-severe plaque psoriasis in adults who are candidates for systemic treatment or phototherapy (ultraviolet or UV light).